ArticleBiomedical engineering online2026
Risk factors and predicted model for clinical relapse after antiviral therapy cessation in chronic hepatitis B patients: a retrospective real-world data analysis.
Article in Biomedical engineering online, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to analyze the risk factors and predicted model for clinical relapse after discontinuation of antiviral therapy in patients with chronic hepatitis B (CHB).
methodsA retrospective analysis was conducted on the clinical data of 99 CHB patients who met the discontinuation criteria and were treated at Southern Central Hospital of Yunnan Province (The First People's Hospital of Honghe State) from March 2020 to December 2022. All subjects received nucleos(t)ide analogs (NAs) or interferon-based antiviral therapy and discontinued treatment once they met the cessation criteria, followed by a 2-year follow-up. Based on relapse status, patients were divided into a relapse group and a non-relapse group. Clinical characteristics were compared between the two groups. A multivariate logistic regression analysis was performed to analyze the independent risk factors for clinical relapse within 2 years after treatment cessation.
resultsDuring the 2-year follow-up, 45 patients (45.45%) experienced clinical relapse after discontinuation. Compared with the non-relapse group, the relapse group exhibited significantly higher age, HBsAg levels at treatment cessation, and HBV DNA load at discontinuation (p < 0.05), as well as a shorter total duration of antiviral therapy (p < 0.05). Multivariate analysis revealed that age, total antiviral treatment duration, HBV DNA load at discontinuation, and HBsAg levels at cessation were independent risk factors for clinical relapse of CHB patients (p < 0.05). A combined predictive model was constructed based on multivariate logistic regression coefficients: combined model = -17.497 + 0.181 × age + (-0.123) × total antiviral duration + 1.746 × HBV DNA at discontinuation + 0.032 × HBsAg at discontinuation. ROC analysis demonstrated that the AUC of the combined model was 0.945 (95% CI: 0.902-0.987) for predicting 2-year clinical relapse, with a sensitivity of 91.11% and specificity of 83.33%. Spearman correlation analysis indicated that patient age and HBV DNA load at discontinuation were negatively correlated with time to relapse (p < 0.05), whereas HBsAg levels showed no significant correlation with total antiviral duration (p > 0.05).
conclusionsAge, HBV DNA load at discontinuation, HBsAg quantification at discontinuation, and the total antiviral duration were identified as key factors influencing clinical relapse after cessation of antiviral therapy in patients with CHB. A predictive model incorporating these factors demonstrated good clinical predictive value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.